NOTICE OF 19TH ANNUAL GENERAL MEETING ("AGM") (2nd AGM POST LISTING)

Notice is hereby given that the Nineteenth Annual General Meeting (AGM') (2nd AGM Post Listing) of the Members of the Company will be held on **Wednesday, September 23, 2026 at 17:00 hours (IST)** through Video Conferencing (VC)/ Other Audio-Visual Means (OAVM) to transact the following businesses:

ORDINARY BUSINESS:

Item 1: Adoption of Financial Statements

To consider and adopt the audited financial statements (including the consolidated financial statements) of the Company for the financial year ended March 31, 2026 and the reports of the Board of Directors ("the Board") and auditors thereon.

Item 2: Re-appointment of Neeraj Sharma (DIN: 09402652), retiring Director

Neeraj Sharma is the Managing Director and was appointed effective March 01, 2024.

Pursuant to Section 152 of the Companies Act, 2013, Neeraj Sharma retires by rotation and being eligible, offers himself for re-appointment as a Director of the Company.

Relevant details of Neeraj Sharma pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India (ICSI) is enclosed as an **Annexure 1** to this Notice.

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

"**RESOLVED** that pursuant to the provisions of section 152 of the Companies Act, 2013 and rules made thereunder (including any statutory modification and re-enactment thereof and other applicable provisions, if any of the Companies Act, 2013, Neerj Sharma (DIN: 09402652) who retires by rotation and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation."

Item 3: Appointment and Fixation of Remuneration of Statutory Auditors:

To consider and, if thought fit, to pass the following resolution with or without modification as an Ordinary Resolution:

"**RESOLVED** that pursuant to the provisions of Sections 139, 142, and other applicable provisions, if any, of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), and based on the recommendation of the Audit Committee and the Board of Directors, M/s. B S R & Co LLP, Chartered Accountants (Firm Registration No.: 101248W/W-100022), be and are hereby appointed as the Statutory Auditors of the Company, to hold office for a period of 5 (five) consecutive years from the conclusion of the 19th Annual General Meeting until the conclusion of the 24th Annual General Meeting of the Company, at such remuneration as may be mutually agreed upon between the Board of Directors of the Company and the Statutory Auditors.

RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorised by the Board) be and are hereby authorised to do all such acts, deeds, matters and things as may be deemed necessary and/or expedient in connection therewith or incidental thereto, to give effect to the foregoing resolution."

Additional information relating to the above agenda is provided on the following pages of this Notice.

SPECIAL BUSINESS:

Item 4: Additional Remuneration payable to Neeraj Sharma (DIN: 09402652), Managing Director for financial year ended March 31, 2026

To consider and, if thought fit, to pass the following resolution with or without modification as a Special Resolution:

"**RESOLVED** that pursuant to Sections 197, 198 and other applicable provisions, if any, of the Companies Act, 2013, (the 'Act') read with Schedule V of the Act and the Rules made thereunder, and applicable provisions, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any amendment(s), modification(s) or re-enactment(s) thereof for the time being in force, pursuant to the Articles of Association of the Company and in continuation to the resolution passed by the Members through postal ballot on July 30, 2025, on the recommendation of the Nomination and Remuneration Committee and as approved by the Board, approval of the Members of the Company be and is hereby accorded for the payment of additional remuneration of INR. 10 million (Indian Rupees Ten Million Only) to Neeraj Sharma (DIN: 09402652), Managing Director of the Company, for the financial year ended March 31, 2026.

RESOLVED FURTHER that all other terms and conditions of appointment and remuneration of Neeraj Sharma, as approved by the Members through postal ballot on July 30, 2025 shall remain the same.

RESOLVED FURTHER that any Director, Anurag Bhagania, Chief Financial Officer and Trisha A, Company Secretary & Compliance Officer of the Company, be and are hereby severally authorised to do all such acts, deeds, matters and things as may be deemed necessary to give effect to this resolution."

Additional information relating to the above agenda is provided on the following pages of this Notice.

Item 5: Commission payable to Non-Executive Independent Directors of the Company

To consider and if thought fit, to pass the following resolution as a Special Resolution:

"RESOLVED that pursuant to the provisions of Sections 149, 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 read with Schedule V thereto, the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Regulation 17(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any statutory amendment(s), modification(s), re-enactment(s) or substitution(s) thereof for the time being in force, the Articles of Association of the Company and pursuant to the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors at their respective meetings held on July 24, 2026, and subject to such other approvals, permissions and sanctions, if any, as may be required, the approval of the Members of the Company be and is hereby accorded for payment of remuneration by way of commission, to each Non-Executive Independent Director of the Company, provided that the aggregate remuneration, including sitting fees paid/payable for the relevant financial year shall not exceed ₹ equivalent of €80,000 (Euro Eighty Thousand Only) per annum, with effect from FY 2025-26, for a period of 3 (three) years.

RESOLVED FURTHER that the commission payable to each Non-Executive Independent Director shall be arrived at after adjusting the sitting fees paid during the relevant financial year.

RESOLVED FURTHER that in the event of absence or inadequacy of profits in any financial year, the Non-Executive Independent Directors shall be eligible for the aforesaid commission.

RESOLVED FURTHER that the Non-Executive Independent Directors shall also be eligible for travel, stay and other incidental expenses incurred by them in connection with the performance of their roles and duties.

RESOLVED FURTHER that the Board (which expression shall include any Committee thereof), Anurag Bhagania, the Chief Financial Officer of the Company and/or such other person(s) authorized by the Board be and are hereby authorised to do all such acts, deeds, matters and things including deciding on the manner of payment of commission and settle all questions or difficulties that may arise with regard to the aforesaid resolution as it may deem fit and to execute any agreements, documents, instructions, etc. as may be necessary or desirable in connection with or incidental to give effect to the aforesaid resolution."

Additional information relating to the above agenda is provided on the following pages of this Notice.

Item No. 6: Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited

To consider and, if thought fit, to pass the following resolution with or without modification as an Ordinary Resolution:

"RESOLVED that pursuant to the provisions of Sections 177, 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the Rules made there under and the Regulation 23(4) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("the Listing Regulations") including any statutory modification(s) or re-enactment(s) thereof for the time being in force read with SEBI Master Circular dated July 11, 2023 (last updated on January 30, 2026) and the Company's Policy on materiality and dealing with related party transactions and in accordance with the omnibus approval and recommendation of the Audit Committee and the Board, and subject to such other approvals as may be necessary, the approval of the Members be and is hereby accorded to the company for entering into and/or continue the material related party transaction(s) with Strides Pharma Science Limited (Strides, India), whether individually or taken together with previous transactions during the financial year 2026-27, which are in the ordinary course of business and on arm's length basis, and which may exceed 10% of the consolidated turnover of the Company, provided that the total value of such transaction(s) shall not exceed INR 3,201 million (~USD 35.6 million) during the said financial year.

RESOLVED FURTHER that all the related parties to the said transaction shall be abstained from voting on this resolution in accordance with the applicable laws and regulations.

RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorized by the Board) be and is hereby authorized to do all such acts, deeds, matters and things and execute all such documents, undertakings and writings as may be necessary, desirable, or expedient to give effect to this resolution, including settling any questions or difficulties that may arise in this regard."

Additional information relating to the above agenda is provided on the following pages of this Notice.

Item 7: Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)

To consider and, if thought fit, to pass the following resolution with or without modification as an Ordinary Resolution:

"RESOLVED that pursuant to the provisions of Sections 177, 188 and other applicable provisions, if any, of the Companies Act, 2013 read with the Rules made there under and the Regulation 23(4) and other applicable provisions of the

Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("the Listing Regulations") including any statutory modification(s) or re-enactment(s) thereof for the time being in force) read with SEBI Master Circular dated July 11, 2023 (last updated on January 30, 2026) and the Company's Policy on materiality and dealing with related party transactions and in accordance with the omnibus approval and recommendation of the Audit Committee and the Board, and subject to such other approvals as may be necessary, the approval of the Members be and is hereby accorded to the company for entering into and/or continue the material related party transaction(s) with Strides Pharma Inc., USA (Strides, USA), whether individually or taken together with previous transactions during the financial year 2026-27, which are in the ordinary course of business and on arm's length basis, and which may exceed 10% of the consolidated turnover of the Company, provided that the total value of such transaction(s) shall not exceed INR 5,663 million (~USD 62.92 million) during the said financial year.

RESOLVED FURTHER that all the related parties to the said transaction shall be abstained from voting on this resolution in accordance with the applicable laws and regulations.

RESOLVED FURTHER that the Board of Directors of the Company (which expression shall include any Committee thereof or person(s) authorized by the Board) be and is hereby authorized to do all such acts, deeds, matters and things and execute all such documents, undertakings and writings as may be necessary, desirable, or expedient to give effect to this resolution, including settling any questions or difficulties that may arise in this regard.

Additional information relating to the above agenda is provided on the following pages of this Notice.

By Order of the Board
For **OneSource Specialty Pharma Limited**

Trisha A
Company Secretary
ICSI Membership No. A47635

Date: July 24, 2026
Place: Bengaluru

Notes:

1. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 (Act) with respect to the special businesses' forms part of the Notice.
2. The Ministry of Corporate Affairs (MCA), Government of India, vide its General Circular No. 14/ 2020 dated April 8, 2020, General Circular No. 17/ 2020 dated April 13, 2020, General Circular No. 20/ 2020 dated May 05, 2020, General Circular No. 10/ 2022 dated December 28, 2022, General Circular No. 09/ 2023 dated September 25, 2023 and General Circular No. 09/2024 dated September 19, 2024 and latest being 3/2025 dated September 22, 2025 (collectively "General Circulars") and Securities and Exchange Board of India (SEBI) vide its Circular No. SEBI/ HO/CFD/ CFDPoD-2/P/ CIR/2023/167 dated October 07, 2023 and Circular No. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 (SEBI Circulars), have permitted companies to conduct General Meetings through Video Conference (VC) or Other Audio Visual Means (OAVM) subject to compliance of various conditions mentioned therein.
3. In compliance with the provisions of the Act, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), General Circulars and SEBI Circulars, AGM of the Company is being held through VC/ OAVM. Members can attend and participate in the AGM through VC/ OAVM only.
4. In compliance with the General Circulars, Notice of the 19th AGM along with the Annual Report for FY26, are being sent only through electronic mode to those Members whose email IDs are registered with the Company/ Depository Participants/ RTA. Communication of assent/ dissent of the Members shall take place only through e-voting.
5. Members may note that the AGM Notice and Annual Report for FY26 shall also be available on the Company's website www. onesourcecdmo.com; website of the Stock Exchanges i.e., BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), and on the website of Integrated Registry Management Services Private Limited (Integrated/ RTA) at https: www.integratedregistry.in.
6. Further, in terms of Regulation 36 (1) (b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015"), a letter containing the web link and path to access the Company's Annual Report is being sent to Members who have not registered their email addresses with the Company, the Depository, RTA.
7. Members who require printed copy of the Annual Report may write to the RTA/ Company at Einward@IntegratedIndia.in or investor-relations@onesourcecdmo.com.
8. Deemed venue for the AGM shall be Registered Office of the Company.
9. Company has appointed NSDL to provide VC/OAVM facility for 19th AGM of the Company.
10. Further, in compliance with the provisions of Section 108 of the Act, read with relevant Rules, Secretarial Standard on General Meetings (SS-2), Regulation 44 of Listing Regulations and General Circulars, the facility for remote e-voting and e-voting in respect of the businesses to be transacted at the AGM is being provided by the Company through NSDL.
11. General instructions for accessing and participating in the AGM through VC/ OAVM Facility and voting through electronic means including remote e-voting is enclosed as **Annexure 4.**
12. Members who have cast their vote by remote e-voting prior to the meeting may attend the meeting but will not be entitled to cast their vote again at the meeting.
13. AGM Live Webcast and two-way conference Facility Pursuant to Regulation 44 of Listing Regulations and Para 3 Clause A (III) of General Circular No. 14/ 2020 dated April 8, 2020 issued by MCA, Government of India, the Company has made arrangements for two-way live webcast of the proceedings of AGM.
14. Details of webcast link shall be made available on the website of the Company at www.onesourcecdmo.com. Facility for joining the AGM through VC/ OAVM shall be open 30 minutes before the scheduled time for commencement of AGM and shall be closed 30 minutes after such scheduled time.
15. In view of AGM being held by VC/ OAVM
    - i) Physical attendance of Members has been dispensed with;
    - ii) The facility for appointment of proxies by the Members shall not be available for the AGM and hence Proxy Form and Attendance Slip are not annexed to this Notice;
    - iii) The Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting.
    - iv) Members attending the AGM through VC shall be counted for the purpose of reckoning quorum under Section 103 of the Act; and
    - v) Route map for the location of the meeting is not provided.
16. Members who have multiple folios in identical names or joint names in the same order are requested to intimate the RTA about these folios to enable consolidation of all such shareholdings into one folio.

ADDITIONAL INFORMATION PURSUANT TO REGULATION 36 OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND SECRETARIAL STANDARD-2 ON GENERAL MEETINGS ISSUED BY THE INSTITUTE OF COMPANY SECRETARIES OF INDIA / STATEMENT SETTING OUT MATERIAL FACTS (EXPLANATORY STATEMENT) PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

In conformity with the provisions of Section 102 of the Companies Act, 2013 read with the Secretarial Standard-2 on General Meetings issued by the Institute of Company Secretaries of India and Regulation 36 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the following explanatory statement and annexures thereto setting - out all material facts relating to Item Nos. 3 to 7 of the accompanying Notice, should be taken as forming part of this Notice.

Item 3: Appointment and Fixation of Remuneration of Statutory Auditors:

The Board of Directors of the Company (the Board), at its meeting held on May 13, 2026, considering the experience and expertise and based on the recommendation of the Audit Committee, has proposed to the Members of the Company, appointment of M/s. B S R & Co LLP, Chartered Accountants (Firm Registration No.: 101248W/W-100022), as Statutory Auditors of the Company in place of Deloitte Haskins & Sells Chartered Accountants (Firm Registration No.:008072S), whose term concludes at this Annual General Meeting (AGM). The proposed appointment is for a term of 5 (five) consecutive years commencing from the conclusion of 19th AGM till the conclusion of the 24th AGM at such remuneration as may be mutually agreed upon between the Board of Directors and the Statutory Auditors, from time to time.

The selection process for the new Statutory Auditors was led by the senior management through a structured evaluation of several audit firms of comparable size and capability. The Chairperson and members of the Audit Committee also interacted with the proposed appointee as part of the evaluation process. Following comprehensive assessment of all proposals and considering various factors such as independence, industry experience, technical skills, geographical presence, team strength, audit quality reports, etc., M/s. B S R & Co. LLP was recommended for appointment as the Statutory Auditors of the Company.

There is no material change in the remuneration proposed to be paid to M/s. B S R & Co LLP, for conducting the Statutory Audit of the financial year ending March 31, 2027 vis-à-vis the remuneration paid to M/s. Deloitte Haskins & Sells, the retiring Statutory Auditors, for the statutory audit of the financial year ended March 31, 2026.

The proposed remuneration to be paid to the Statutory Auditors for the FY 2026-27 is ₹ 5.2 Million (Rupees Nine Million Six Hundred Thousand Only). The said remuneration excludes fees for limited review (₹ 3.2 million), one-time opening balance sheet review (₹1.2 million), ad hoc certifications (₹ 0.1 million per certificate), applicable taxes, administrative charges, and reimbursement of out-of-pocket expenses.

Profile of M/s. BSR & Co. LLP.:

- M/s B S R & Co. ('the firm') was constituted on 27th March 1990 as a partnership firm having firm registration no. as 101248W. It was converted into Limited Liability Partnership i.e. B S R & Co. LLP on 14th October 2013 thereby having a new firm registration no. 101248W/W-100022.
- The registered office of the firm is at 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai - 400063. M/s. BSR & Co. LLP is a member entity of B S R & Affiliates, a network registered with the Institute of Chartered Accountants of India.
- It has its head office in Mumbai and operates through 14 locations across India. M/s. B S R & Co. LLP has a strength of over 4,000 personnel and 170 partners and serves as statutory auditor to several companies listed on stock exchanges in India including companies in the Pharma and Life Sciences sector.
- Pursuant to Section 139 of the Companies Act, 2013 (the Act) and the Rules framed thereunder, the Company has received written consent from M/s. BSR & Co. LLP, Chartered Accountants, to act as the Statutory Auditors of the Company, along with a certificate confirming that they satisfy the eligibility criteria prescribed under Section 141 of the Act and that the appointment, if made, shall be in accordance with the applicable provisions of the Act and Rules made thereunder.
- Further as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, M/s. BSR & Co. LLP, has confirmed that they hold a valid Peer Review certificate issued by the Peer Review Board of Institute of Chartered Accountants of India (ICAI).

None of the Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No.3.

The Board recommends the resolution set out at Item No. 3 for the approval of by Members as an Ordinary Resolution.

Item 4: Additional Remuneration payable to Neeraj Sharma (DIN: 09402652), Managing Director for financial year ended March 31, 2026

Neeraj Sharma (DIN: 09402652), is a Managing Director and was appointed effective March 01, 2024.

Neeraj's remuneration, applicable for a period upto March 31, 2028 as Managing Director was approved by the Members of the Company through postal ballot on July 30, 2025, as under:

- *Revised remuneration, effective 1st April 2025: INR 65.87 million per annum (inclusive of fixed pay, target performance bonus not exceeding INR 16.87 million, and Long-term Incentive Plan [LTIP])*
- *Neeraj Sharma will be entitled for annual increments as may be recommended/approved by the Nomination and Remuneration Committee/ Board of Directors and such annual increment shall not exceed 30% of the then existing remuneration on CTC basis*
- *Other benefits, terms and conditions shall remain in line with the appointment letter issued to him by the Company including such addendums/amendments, if any, as made in accordance with Company policies*

Since the remuneration approved by the Members of the Company was denominated in Indian Rupees, Neeraj Sharma, being a Dutch citizen, suffered significant impact to his earnings due to foreign exchange fluctuation arising as a result of ongoing geo-political developments. The Indian Rupee has significantly depreciated over the last year and in order to compensate the impact of exchange rate fluctuation, the Board of Directors at their meeting held on May 13, 2026, based on the recommendation of the Nomination and Remuneration Committee, approved an additional payout of INR 10 Million (Indian Rupees Ten Million only), subject of the approval of the Members.

The proposed payment, once approved by the Members shall be in addition to the remuneration previously approved by the Members and shall form part of the overall remuneration payable to Neeraj Sharma for FY 25-26 in accordance with Sections 197 and 198 of the Act read with Schedule V thereto and other applicable provisions of the Act.

Except for the aforesaid revision in remuneration, all other terms and conditions of appointment and remuneration of Neeraj as approved by the Members on July 30, 2025 through postal ballot, will remain unchanged. This revision does not involve any variation in terms of appointment or tenure

Additional disclosures required under Schedule V to the Companies Act, 2013 in respect of revision in remuneration forms part of **Annexure 2** to this notice.

The Company has not defaulted in payment of dues to any bank or public financial institution or non-convertible debenture holders or other secured creditor, if any.

None of the Directors or Key Managerial Personnel of the Company or their relatives, except Neeraj Sharma, is in any way, concerned or interested, financially or otherwise, in the resolution.

The Board recommend the resolution set out at Item No. 4 for approval by the Members as a Special Resolution.

Item 5: Approval for commission payable to Non-Executive Independent Directors of the Company

Background:

OneSource was listed on the bourses on January 24, 2025 consequent to a business combination of multiple legal entities through a Scheme of Arrangement. The legal entities combined over decades of manufacturing and quality excellence in distinct capabilities of DDC, Biologics, Injectables, Softgel as one integrated offering to deliver contract development and manufacturing services for global pharmaceutical customers.

Keeping the needs of the emerging global business needs, one of the immediate priorities outlined by the Promoters and the Management team was to build a strong board to guide the experienced leadership team and to inculcate best global practices from inception across all functions, with specific focus on governance, sustainability and risk. To this direction, we have built a marquee Board comprising 8 directors, out of which 5 (five) are non-executive independent directors with global insights in running businesses. They bring together deep industry knowledge, diverse perspectives and complementary expertise across business, management, finance, governance and capital markets.

The Board was reconstituted in February 2025 and further on June 2025 and the Company currently has 5 Independent Directors.

The Company currently has a highly accomplished, international Board with a diverse mix of skills and experience to support its evolving business strategy and early-stage CDMO journey. The Non-Executive Independent Directors bring extensive expertise across strategic leadership, industry network, operations, finance, risk management, governance and global business, complemented by diverse geographical backgrounds and international experience. Their active participation in the deliberations of the Board and its Committees provides independent judgement, balanced decision-making and valuable strategic guidance to the Management. Their industry insights, understanding of global best practices, awareness of emerging technology trends, and extensive professional networks enable management to develop strategic perspectives, identify growth opportunities, engage key stakeholders, support long-term value creation and sustainable growth

The company had proposed for a board level uniform compensation package with the Independent Directors at the time of induction which was formally recommended / approved by the Nomination and Remuneration Committee and Board respectively.

Statutory provision:

As per the provisions of Sections 149, 197, 198 and other applicable provisions, if any of the Companies Act, 2013 read with Schedule V and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (“the Rules”) and Regulation 17(6) of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 and taking into account the roles and responsibilities of the Independent Directors, it is proposed to pay remuneration by way of commission to the each Non-Executive Independent Director of the Company, with effect from FY 2025-26, for a period of 3 (three) years.

Approval sought:

In recognition of their expertise, time commitment and contribution towards strengthening the Company’s governance framework and supporting its long-term growth, the Nomination and Remuneration Committee, at its meeting held on July 24, 2026, recommended the payment of commission to the Non-Executive Independent Directors. The Board of Directors, at its meeting held on July 24, 2026, approved the recommendation, for payment of commission as stated in the resolution, subject to the approval of the Members.

Additional disclosures required under Schedule V to the Companies Act, 2013 in respect of revision in remuneration forms part of **Annexure 2** to this notice.

The Company has not defaulted in payment of dues to any bank or public financial institution or non-convertible debenture holders or other secured creditor, if any.

Except for the Non-Executive Independent Directors, none of the other Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution.

The Board of Directors recommends the Special Resolution as set out at Item No. 5 of the Notice for approval of the Members.

Item No. 6: Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited ("Strides India")

As per the provisions of Sections 177, 188 of the Companies Act, 2013 ("Act"), transactions with related parties which are on an arm's length basis and in the ordinary course of business, are exempt from the requirement of obtaining prior approval of Members. However, pursuant to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), all material transactions requires the prior approval of Members through an Ordinary Resolution, notwithstanding the fact that the same are on an arm's length basis and in the ordinary course of business. Further, no related party shall vote to approve such resolution irrespective of whether such related party is a party to the particular transaction.

In terms of Regulation 23 (1) of SEBI Listing Regulations, a related party transaction shall be considered material if the value of transaction(s) individually or taken together with previous transactions during a financial year, exceeds the materiality thresholds specified in Schedule XII to the SEBI Listing Regulations. In case of your Company, the threshold considered would be ten percent of the annual consolidated turnover of the Company as per the last audited financial statements of the Company.

Further, SEBI vide its circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated June 26, 2025 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/135 dated October 13, 2026, has notified the Industry Standards on "Minimum information to be provided to the Audit Committee and Members for approval of Related Party Transactions" ('Industry Standards') effective immediately, i.e., October 13, 2025 which inter alia requires listed entity(ies) to provide minimum information, in specified format, relating to the proposed RPTs including material modifications, to the Audit Committee and to the Members, while seeking approval.

Members may kindly note that Strides India ("Strides"), is a related party of the company in terms of Section 2(76) of the Act and Regulation 2(1) (zb) of the SEBI Listing Regulations. The Company, as part of its ordinary course of business has entered into/ proposed to enter into agreements/ arrangements/transactions with Strides India at arm's length basis.

Background for the RPTs / proposed RPTs

Formation of OneSource

On 25th September 2023, the Board of Directors of (1) OneSource Specialty Pharma Limited (formerly Stelis Biopharma Limited), (2) Strides Pharma Science Limited and (3) Steriscience Specialties Private Limited, approved a Scheme of Arrangement ("Scheme") to bring together the Soft Gelatine business of Strides India, Complex Injectables business of Steriscience and Biologics CDMO business of the Company to create OneSource, a multimodal pure-play specialty pharmaceutical CDMO.

The Scheme received overwhelming support from the Members and creditors and was approved by the Hon'ble National Company Law Tribunal, Mumbai Bench vide its order dated November 14, 2024 (certified copy of which was received on November 26, 2024) and the Company's equity shares were listed on NSE and BSE on January 24, 2025.

In terms of the Scheme, Identified CDMO Business and Soft Gelatin Business of Strides India became part of the Company and as per the Scheme Identified CDMO Business and Soft Gelatin Business included the business of manufacturing of oral soft gelatins for its customers and under contract development and manufacturing arrangement, carried on by Strides India at the plant located at KRS Gardens, Bangalore, along with related assets, customer contracts, employees, and intellectual properties.

Pursuant to the above, Company has entered into a manufacturing and support service agreement dated November 16, 2024 with Strides India, by virtue of which your Company has access and manufacturing rights within the premise situated at KRS Gardens, Suragajakkanahalli, Bengaluru south, Jigani - Anekal Rd, Bengaluru-562 106, Karnataka

In view of the above arrangement, the Company will continue to have related party transaction with Strides India for the next few years. The Company has a long-term vision to build an independent facility for soft gelatin capsules within next four years.

Members are informed that the Audit Committee and the Board of Directors, at their respective meetings, have reviewed and approved the proposed related party transactions and recommend the same for approval by the Members as an Ordinary Resolution. The approval sought under this resolution shall be valid for the period from April 1, 2026 to March 31, 2027.

Details of the proposed Related Party Transactions ("RPT") between the Company and Strides India, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 read with the Industry Standard on Minimum information provided to the Members for approval of Related Party Transactions are provided in **Annexure 3A** to this notice.

Except Arun Kumar, Promoter and Non-Executive Director (DIN: 00084845) of the company, none of the other Directors and Key Managerial Personnel of the Company and/or their respective relatives are concerned or interested, financially or otherwise, in the resolution.

Basis the rationale and justification provided above, the Board recommends the ordinary resolution under Item No. 6 of the accompanying Notice for prior approval of Members.

Item 7: Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited, India) ("Strides USA")

As per the provisions of Section 177, 188 of the Companies Act, 2013 ("Act"), transactions with related parties which are on an arm's length basis and in the ordinary course of business, are exempt from the requirement of obtaining prior approval of Members. However, pursuant to Regulation 23(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") all material transaction requires the prior approval of Members through an Ordinary Resolution, notwithstanding the fact that the same are on an arm's length basis and in the ordinary course of business. Further, no related party shall vote to approve such resolution irrespective of whether such related party is a party to the particular transaction.

In terms of Regulation 23 (1) of SEBI Listing Regulations, a related party shall be considered material if the value of the transaction(s) individually or taken together with previous transactions during a financial year, exceeds the materiality thresholds specified in Schedule XII to the SEBI Listing Regulations.

Further, SEBI vide its circular SEBI/HO/CFD/CFD-PoD-2/P/CIR/2025/93 dated June 26, 2025 has notified the Industry Standards on "Minimum information to be provided to the Audit Committee and Members for approval of Related Party Transactions" ('Industry Standards') effective September 1, 2025 which inter alia requires listed entity to provide minimum information, in specified format, relating to the proposed RPTs including material modifications, to the Audit Committee and to the Members, while seeking approval.

Members may kindly note that Strides USA is a related party of the company in terms of Section 2(76) of the Act and Regulation 2(1) (zb) of the SEBI Listing Regulations. The Company as part of its ordinary course of business has entered into/proposed to be entered into agreements/arrangements/transactions with the Company at arm's length basis.

Background for the RPTs/ proposed RPTs:

Pursuant to the approved scheme of arrangement, the soft gelatine business of Strides India was acquired by OneSource. The front-end operations for the soft gelatine business in the US market continue to be performed through Strides USA.

As explained under explanatory statement to Item No. 7 of this notice, OneSource was formed through a scheme of arrangement with Strides India wherein Identified CDMO Business and Soft Gelatin Business became part of OneSource.

Strides India business model for Softgel business included using Strides USA, as a front-end partner in US market. As a pure play specialty pharma CDMO OneSource operates in B2B segment, in the contrast Strides USA is B2C focused. This arrangement helps OneSource to strategically navigate through the front-end operations in US market.

OneSource proposes to continue the same structure for selling products in US markets through Strides USA at arm's length basis. It may be noted that Strides India is one of the multiple other customers and partners in US and Europe.

Members are kindly informed that the Audit Committee and the Board of Directors, at their respective meetings, have reviewed and approved the proposed related party transactions and recommend the same for approval by the Members as an Ordinary Resolution. The approval sought under this resolution shall be valid for the period from April 1, 2026 to March 31, 2027.

Details of the proposed Related Party Transactions ("RPT") between the Company and Strides, including the information required to be disclosed in the Explanatory Statement pursuant to the SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 read with the Industry Standard on Minimum information provided to the Members for approval of Related Party Transactions are provided in **Annexure 3** to this notice.

Except Arun Kumar, Promoter and Non-Executive Director (DIN: 00084845) of the company, none of the other Directors and Key Managerial Personnel of the Company and/or their respective relatives are concerned or interested, financially or otherwise, in the resolution.

Basis the rationale and justification provided above, the Board recommends the ordinary resolution under Item No. 7 of the accompanying Notice for prior approval of Members.

By Order of the Board
For **OneSource Specialty Pharma Limited**

Trisha A
Company Secretary
ICSI Membership No. A47635

Date: July 24, 2026
Place: Bengaluru

Annexure 1

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 issued by the Institute of Company Secretaries of India, the following information is furnished about the Directors proposed to be re-appointed

Brief Profile of Neeraj Sharma

Neeraj Sharma brings over 30 years of global pharmaceutical experience across India, South-East Asia, Latin America and Europe. A seasoned P&L leader, he has successfully guided businesses through market entry, accelerated growth, operational turnarounds and M&A integrations across both regulated and emerging markets.

He joined the Group in 2021 and previously served as CEO of Steriscience. Prior to that, he spent 25 years with Ranbaxy and Sun Pharma, most recently leading the Generics Business for Western Europe.

Other details of Neeraj Sharma, pursuant to Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard-2 are as below:

DIN	09402652
Age	54 years
Qualification	MBA from London Business School. A Fellow of the Institute of Chartered Accountants in England and Wales
Experience and nature of expertise in specific functional area (brief resume)	Strong corporate governance, ESG, mergers and acquisitions (M&A), financial management, strategic and operational expertise (refer brief profile above)
Date of first appointment on the Board	March 01, 2024
Terms and conditions of appointment	Managing Director (liable to retire by rotation)
Details of remuneration, if any	As approved by the Members through postal ballot on July 30, 2025 read with the additional payout proposed under Item No. 4 of this AGM notice
Shareholding in the Company (number of shares as on the date of this AGM Notice)	56,148 equity shares
Relationship with other Directors, Manager and other Key Managerial Personnel (inter-se)	None
Number of Board Meetings /Committee meetings attended during FY25-26	• Board Meeting: 6 out of 6 meetings attended • Audit Committee Meetings: 5 out of 6 meetings attended • Risk Management Committee Meeting: 2 out of 2 meetings attended • Stakeholders' Relationship Committee Meeting: 1 out of 1 meeting attended • Corporate Social Responsibility Meeting: 1 out of 1 meeting attended
Directorships held in other companies* (upto the date of this AGM Notice)	None
Membership/ Chairmanship of Committees in other Public Companies#	None
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years	None

*Does not include foreign Companies and private Companies.

#Includes Membership/Chairmanship of Audit Committee and Stakeholders' Relationship Committee only

Annexure 2

Additional disclosures as per Section 197 read with Schedule V of the Act in respect of Item No. 4 & 5 of the Notice.

I. General Information

1.	Nature of Industry	Pharmaceutical
2.	Date or expected date of commencement of commercial production	Not applicable as the Company is an existing Company
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus.	Not applicable as the Company is an existing Company
4.	Financial performance based on given Indicators	Mentioned below

Particulars	Standalone (INR in Millions)			Consolidated (INR in Millions)		
	2025-26	2024-25	2023-24	2025-26	2024-25	2023-24
Total Revenue	14,203.89	13,172.71	1,761.44	14,366.12	14,623.27	1,761.44
Total Expense (excluding exceptional items)	13,937.59	12,264.76	4,251.44	15186.46	14,185.48	4,258.99
Profit After Tax (PAT)	212.10	193.10	(3,904.02)	(738.03)	(179.71)	(3,911.65)

5.	Foreign Investment or collaborations, if any	The Company is listed at National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). As on March 31, 2026, foreign holding in the company was at 25.67%

II. Information about the Appointee: (Refer Item No. 4 of the Notice)

II (a) Managing Director & Chief Executive Officer: Neeraj Sharma

1. Background details, Recognition/ Awards, Job Profile and Suitability to the role

Neeraj Sharma, aged 54, is a Dutch citizen with an illustrious career spanning over 30 years in the global pharmaceutical industry. He has lived and worked across diverse markets, including India, South-East Asia, Latin America, and Europe, bringing a rich cross-cultural perspective to his leadership roles. His detailed profile is given in **Annexure 1** to this notice.

2. Past Remuneration, Proposed Remuneration & Comparative remuneration and Pecuniary relationship, if any

- **Past Remuneration:** INR 62.45 million (inclusive of fixed, target performance bonus and long-term incentive plan) in total was paid as remuneration during the financial year 2025-26

- **Proposed Remuneration:** Please refer to the resolution at Item No. 4. The proposed additional payout is primarily to offset the impact of exchange rate fluctuation in the past financial year arising out of geo-political developments. The rationale for the payout is stated in the explanatory statement to Item No. 4 of this notice in Page 405

- **Comparative remuneration:** Considering Neeraj Sharma's extensive experience, expertise and leadership capabilities, as well as the strategic requirements of to drive the challenging business, the proposed remuneration is considered appropriate and broadly aligned with the remuneration paid to the Managing Director & Chief Executive Officer (CEO) of similar companies in the industry

Proposed additional remuneration recommended by NRC and approved by the Board is in line with the guidelines of the Nomination and Remuneration Policy of the Company and aligns with the short-term and long-term business objectives of the Company.

- **Pecuniary relationship:** Neeraj Sharma has no pecuniary relationship with the Company other than the remuneration paid or payable to him in his capacity as the Managing Director of the Company. He is not related to any director/ key managerial personnel of the Company

ANNEXURE II(a)

DETAILS OF DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT

II (a) Information about the appointees - Non-Executive Independent Directors (Refer Item 5 of the Notice)

Director Particulars and Remuneration

Past Remuneration	Nil Details of sitting fees paid are disclosed separately in the Corporate Governance report forming part of the Annual Report.
Proposed Remuneration	• Remuneration by way of commission, and sitting fees to each Non-Executive Independent Director of the Company, amount not exceeding the ₹ equivalent of €80,000 (Euro Eighty Thousand Only) per annum, with effect from FY 2025-26, for a period of 3 (three) years • Commission payable to each Independent Director shall be arrived at after adjusting the sitting fees paid during the relevant financial year • In the event of absence or inadequacy of profits in any financial year, the Non-Executive Independent Directors shall be eligible for the above commission

Additional information

1. Debarati Sen (DIN: 07521172)

Background details	Debarati Sen is a seasoned global business leader with a track record of driving transformative business performance. She is currently the Chief Commercial Officer at Kingfisher plc, Europe's leading home improvement retailer. Previously, she held leadership roles at HMTX Industries, most recently serving as CEO, after having served as the Group President. She has led growth and strategic initiatives across industrial and consumer businesses, including heading the largest division in 3M's Consumer Business Group with brands like Filtrete™, Command™ and ScotchBlue™. She previously served as CEO and Managing Director of 3M India Limited and is an active leader in nonprofit and academic boards, including the Centre for Victims of Torture (CVT), an international humanitarian organisation, and the Carlson School of Management.
Job profile and suitability	The Company will continue to benefit from her exceptional leadership and proven ability to drive transformative business performance, demonstrated through her strong track record of delivering sustainable growth and strategic transformation.
Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	In view of the significant responsibilities undertaken by the Independent Directors in providing strategic guidance, governance oversight, and independent judgment, the proposed commission is considered fair and aligned with prevailing industry practices for similarly sized and comparable companies.
Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any	None
Membership/Chairmanship of Committees across other Companies (excluding foreign companies)	Nil
List of Directorships held in other Companies (excluding foreign companies)	Nil
Number of shares held in the Company	Nil
Details of Board Meetings attended by the Director during the year	6 (6)
Number of Committee Meetings attended by Director during the year	11(11)

2. Dr. Claudio Albrecht (DIN: 10905781)

Background details	Dr. Claudio Albrecht is Co-Founder and Managing Partner of Albrecht, Prock & Partners AG, a Zug-based strategic advisory firm focused on pharmaceutical acquisitions and investments. With over three decades of experience in generics industry, he has served as CEO of Ratiopharm Group, Actavis Group and STADA AG. He began his career at Sandoz and later led generics operations across the Netherlands, Germany, and the United States. As CEO of Ratiopharm Group, he led its international expansion and initiated its biosimilars programme. He co-founded CoMeth and later led Actavis through a major turnaround, culminating in its US$6 billion sale to Watson. He also played a key role in the leveraged buyout of STADA AG and in developing a comprehensive diabetes generics platform.
Job profile and suitability	The Company will continue to benefit from his understanding of pharmaceutical strategy and global market dynamics.
Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	In view of the significant responsibilities undertaken by the Independent Directors in providing strategic guidance, governance oversight, and independent judgment, the proposed commission is considered fair and aligned with prevailing industry practices for similarly sized and comparable companies.
Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any	None
Membership/Chairmanship of Committees across other Companies (excluding foreign companies)	Dr. Reddy's Labs: • STO committee and • Risk Management Committee
List of Directorships held in other Companies (excluding foreign companies)	Dr. Reddy's Laboratories Ltd.
Number of shares held in the Company	Nil
Details of Board Meetings attended by the Director during the year	5 (6)
Number of Committee Meetings attended by Director during the year	1 (2)

3. Colin Michael Bond (DIN: 10982819)

Background details	Colin Michael Bond is a seasoned global finance executive with over 15 years of experience serving as CFO of publicly listed companies across Switzerland, Germany, and the United States. In addition to his CFO roles, he has completed full-term tenures as Board Member and Audit Committee Chairman for listed companies in Switzerland, the UK, and Germany. His career is distinguished by a strong track record of high-impact corporate transactions, including two IPOs, a corporate spin-off, a sale to private equity, an acquisition followed by delisting, a sale and subsequent delisting, multiple public bond issuances, and several material M&A activities. Colin also has significant experience in corporate governance and strategy development and execution, coupled with operational expertise in leading Audit and Risk Committees, business transformation, digitalisation, IT integration, and ESG initiatives. A Fellow of the Institute of Chartered Accountants in England and Wales, he earned his MBA from London Business School and holds a BSc in Pharmacy with Upper Second Class Honours from the University of Aston in Birmingham. He became a Member of the Royal Pharmaceutical Society of Great Britain in 1985.
Job profile and suitability	The Company will continue to benefit from his distinguished experiences in two IPOs, a corporate spin-off, a sale to private equity, acquisitions followed by delisting, and multiple public bond also the experiences relating to mergers and acquisitions, corporate governance, and strategy development and execution.

Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	In view of the significant responsibilities undertaken by the Independent Directors in providing strategic guidance, governance oversight, and independent judgment, the proposed commission is considered fair and aligned with prevailing industry practices for similarly sized and comparable companies.
Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any	None
Membership/Chairmanship of Committees across other Companies (excluding foreign companies)	Nil
List of Directorships held in other Companies (excluding foreign companies)	Nil
Number of shares held in the Company	Nil
Details of Board Meetings attended by the Director during the year	5 (5)
Number of Committee Meetings attended by Director during the year	5 (5)

4. Dr. Rashmi H. Barbhaiya (DIN: 10982819)

Background details	Dr. Rashmi H. Barbhaiya is a globally respected pharmaceutical executive and a serial entrepreneur with deep expertise in drug development, innovation and the successful creation of pharmaceutical and contract research ventures. He spent 21 years at Bristol-Myers, where he played a pivotal role in the development of breakthrough therapies across AIDS, oncology and cardiovascular disease. In 2002, he joined Ranbaxy Laboratories as President of R&D, leading a team of over 900 scientists and establishing a landmark R&D alliance with GlaxoSmithKline, the first-of-its-kind by an Indian pharmaceutical company. Following his tenure at Ranbaxy, Rashmi co-founded Advinus Therapeutics, a discovery-driven pharmaceutical venture with early clinical development capabilities and strategic partnerships with Takeda, Merck, and Novartis. He currently serves on global advisory boards focused on neglected diseases and biotech innovation, and is a co-founder of Apinova Pharma Innovations, which aims to strengthen US-based Active Pharmaceutical Ingredient (API) manufacturing.
Job profile and suitability	The Company will continue to benefit from his driving innovation, drug development, and building successful pharma and CRO companies.
Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	In view of the significant responsibilities undertaken by the Independent Directors in providing strategic guidance, governance oversight, and independent judgment, the proposed commission is considered fair and aligned with prevailing industry practices for similarly sized and comparable companies.
Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any	None
Membership/Chairmanship of Committees across other Companies (excluding foreign companies)	NIL
List of Directorships held in other Companies (excluding foreign companies)	NIL
Number of shares held in the Company	Nil
Details of Board Meetings attended by the Director during the year	6 (6)
Number of Committee Meetings attended by Director during the year	1 (1)

5. Vijay Paul Karwal (DIN: 10982819)

Background details	Vijay Paul Karwal is a Managing Director at CBC Group, Asia's largest healthcare-dedicated asset management firm with an AUM of approximately US$11 billion. Based in Singapore, Vijay brings over 25 years of global experience in healthcare investment, management and advisory, with deep expertise in strategy, business development, M&A and capital raising. At CBC, he advises on sourcing and execution of investment opportunities as well as portfolio management, leading regional South-East Asia coverage for the firm, together with supporting global origination for CBC's royalty & private credit investment funds. Prior to his current role, Vijay served as an Operating Partner at CBC and held leadership positions, including Executive Director, CEO and CFO at AffaMed Therapeutics, a CBC portfolio company. His career spans senior investment banking roles at Nomura International, CIMB Investment Bank, RBS, ABN AMRO and ABN AMRO Rothschild, as well as operational leadership at DaVita Inc. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector representing over US$95 billion in transaction value, gaining extensive global experience across postings in London, Chicago, New York, Hong Kong and Singapore. Vijay was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands. He holds an MSc in Economics and is also a CFA charter holder.
Job profile and suitability	The Company will continue to benefit from his distinguished experience in capital deployment and portfolio management for the private equities and royalty & private credit investment funds.
Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	In view of the significant responsibilities undertaken by the Independent Directors in providing strategic guidance, governance oversight, and independent judgment, the proposed commission is considered fair and aligned with prevailing industry practices for similarly sized and comparable companies.
Pecuniary relationship directly or indirectly with the company, or relation with the managerial personnel, if any	None
Membership/Chairmanship of Committees across other Companies (excluding foreign companies)	Nil
List of Directorships held in other Companies (excluding foreign companies)	Nil
Number of shares held in the Company	Nil
Details of Board Meetings attended by the Director during the year	6 (6)
Number of Committee Meetings attended by Director during the year	11 (11)

Reasons of loss or inadequate profits, steps taken or proposed to be taken for improvement and expected increase in productivity and profits in measurable terms:

The Company is in a growth and investment phase and has made significant investments in capacity expansion, technology platforms, and capability enhancement to strengthen its long-term competitive position and support future growth. The impact of these investments, together with acquisition integration and related costs, has affected profits during the relevant period.

Notwithstanding the above, the Company's underlying operating performance has remained strong, supported by a growing commercial pipeline, deeper customer engagements, growth in high-value specialty platforms such as GLP-1s and Biologics, and continued improvements in operational efficiency. The Company has also benefited from successful integration initiatives, resulting in cross-selling opportunities, cost synergies, and enhanced value creation.

Going forward, the Company expects further improvement in productivity and profitability through higher utilisation of existing and expanded capacities, execution of capital expenditure projects, increasing contribution from higher-margin products and services, continued customer acquisition, and operational excellence initiatives. The strong recovery demonstrated in Q4 FY26, with revenue growth of 47% and EBITDA growth of over 5x year-on-year, reinforces the Company's confidence in its growth trajectory. The Company has also reaffirmed its FY28 outlook of $400 million organic revenue with an EBITDA margin of approximately 40%, reflecting its confidence in delivering sustainable growth and long-term value for Members.

Annexure 3

Details of the proposed transactions with Strides Pharma Science Limited (Strides India) being the related party of the Company, including the information pursuant to Clause 4 of the Standards read with applicable laws and as placed before the Audit Committee for consideration while seeking prior approval of the proposed RPT(s), are provided below:

PART-A

Minimum information of the proposed RPT, applicable to all RPTs

SN	Particulars of the information	Information provided by the Management
A(1)	**Basic details of the related party**	
1.	Name of the related party	Strides Pharma Science Limited
2.	Country of incorporation of the related party	India
3.	Nature of business of the related party	Engaged in developing, manufacturing, and marketing generic and specialty medicines across regulated and emerging markets.
A(2)	**Relationship and ownership of the related party**	
1.	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party, including nature of its concern (financial or otherwise) and the following:	Strides India and OneSource Specialty Pharma Limited have a common promoter and Strides India, is a related party of the company in terms of Section 2(76) of the Act and Regulation 2(1) (zb) of the SEBI Listing Regulations
	- Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party.	Nil
	- Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary).	NA
	- Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity/ Subsidiary/related party has control (as defined under SEBI Listing Regulations). While calculating indirect shareholding, shareholding held by relatives shall also be considered.	Arco Lab Private Limited, wholly owned subsidiary of Strides India is holding 1.61% in OneSource
A(3)	**Details of previous transactions with the related party**	
1.	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year.	See table below. No Transactions undertaken by the Subsidiary with the related party during the previous year

SN	Category	Amount (₹ in Mn) FY25-26
1)	Sale of Goods	467.54
2)	Purchase of Goods	126.93
3)	Receiving of Services	1,157.16
5)	Others	99.09
	- Reimbursement of expenses	96.92
	- Purchase of Property, Plant & Equipment	2.17
	Total	**1,850.72**

No Transactions undertaken by the Subsidiary with the related party during the previous year

SN	Particulars of the information	Information provided by the Management
2.	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought. (amount in million including GST)	see table below; No Transactions undertaken by the Subsidiary with the related party during the current year
3.	Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year.	No
A(4)	**Amount of the proposed transaction(s)**	
1.	Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ Members. (amount in million including GST)	₹ 3,201 million
2.	Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?	Yes
3.	Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year	22.52%
4.	Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction)	NA
5.	Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available	6.59%
6.	Financial performance of the related party for the immediately preceding financial year: Explanations: The above information is given on standalone basis.	see table below

Item 2 – Information provided by the Management:

SN	Category	Amount (₹ in Mn) Q1FY26-27
1)	Sale of Goods	18.36
2)	Receiving of Services	287.54
3)	Others	1.11
	- Reimbursement of expenses	1.11
	- Purchase of Property, Plant & Equipment	-
	Total	**307.01**

No Transactions undertaken by the Subsidiary with the related party during the current year

Item 6 – Information provided by the Management:

Particulars	Amount (₹ in Mn) for FY2025-26
Turnover	21,801.35
Profit After Tax	1,836.35
Net worth	32,835.18

<table>
<tr><th>SN</th><th>Particulars of the information</th><th>Information provided by the Management</th></tr>
<tr><td colspan="3">A(5) Basic details of the proposed transaction</td></tr>
<tr><td>1.</td><td>Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)</td><td>The Company received scheme approval from the Hon'ble NCLT on November 27, 2024. As a result of the Scheme, the soft gelatine business of Strides India was acquired by OneSource. The Company has entered into an agreement with Strides India under which the Company will have access to and manufacturing rights within the premises situated at KRS Gardens under loan licence arrangement. To support this arrangement, Strides India will charge a monthly job work fee and admin charges and manage the manufacturing process. This transaction is carried out at an arm's length price (ALP) and has been assessed in the previous financial year. The same principle for pricing is applied in the current financial year</td></tr>
<tr><td>2.</td><td>Details of each type of proposed transactions for FY2026-27</td><td><table>
<tr><th>SN</th><th>Category</th><th>Amount (₹ in Mn)</th></tr>
<tr><td>1)</td><td>Sale of Goods</td><td>1,000.00</td></tr>
<tr><td>2)</td><td>Purchase of Goods</td><td>500.00</td></tr>
<tr><td>3)</td><td>Receiving of Services</td><td>1,601.00</td></tr>
<tr><td>4)</td><td>Others</td><td>100.00</td></tr>
<tr><td></td><td>- Reimbursement of expenses</td><td>100.00</td></tr>
<tr><td></td><td>Total</td><td>3,201.00</td></tr>
</table></td></tr>
<tr><td>3.</td><td>Tenure of the proposed transaction (tenure in number of years or months to be specified)</td><td>April'26 to March'27</td></tr>
<tr><td>4.</td><td>Whether omnibus approval is being sought?</td><td>Yes</td></tr>
<tr><td>5.</td><td>Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise</td><td>₹ 3,201.00 million</td></tr>
<tr><td>6.</td><td>Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity</td><td>Following the implementation of the Scheme pursuant to NCLT Order, the Company has entered into a manufacturing and support service agreement dated November 16, 2024 with Strides India by virtue of which our Company has access and manufacturing rights within the premise situated at KRS Gardens. This agreement shall remain in force up to 31st March 2029. The Company has a vision to build an independent facility for soft gelatin capsules within the time frame. These transactions are necessary in nature to continue the soft gelatin business.</td></tr>
<tr><td>7.</td><td>Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly</td><td>Arun Kumar is the Non-Executive Director ('NED') and Chairman of OneSource.</td></tr>
<tr><td>8.</td><td>A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee</td><td>NA</td></tr>
<tr><td>9.</td><td>Other information relevant for decision making</td><td>All important information forms part of the Statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice.</td></tr>
</table>

PART-B

Information to be provided only if a specific type of RPT as mentioned below is proposed to be undertaken and is in addition to Part A

B(1). Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances

1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services	NA since this is specific in nature and not comparable
2.	Basis of determination of price	The Pricing is determined basis the annual Transfer Pricing study by external third-party specialist, which is in accordance with applicable regulations
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: a. Amount of Trade advance b. Tenure c. Whether same is self-liquidating?	NA

Details of the proposed transactions with Strides Pharma Inc, USA (Strides USA) (a WOS of Strides Pharma Science Limited) (Strides India) being the related party of the Company, including the information pursuant to Clause 4 of the Standards read with applicable laws and as placed before the Audit Committee for consideration while seeking prior approval of the proposed RPT(s), are provided below:

PART-A

Minimum information of the proposed RPT, applicable to all RPTs

SN	Particulars of the information	Information provided by the Management
A(1)	**Basic details of the related party**	
1.	Name of the related party	**Strides Pharma Inc, USA**
2.	Country of incorporation of the related party	USA
3.	Nature of business of the related party	Develops, manufactures, and markets affordable generic medicines in the U.S.
A(2)	**Relationship and ownership of the related party**	
1.	Relationship between the listed entity/subsidiary (in case of transaction involving the subsidiary) and the related party, including nature of its concern (financial or otherwise) and the following:	Strides USA, (a WOS of Strides India) and OneSource Specialty Pharma Limited have a common promoter and is a related party of the company in terms of Section 2(76) of the Act and Regulation 2(1) (zb) of the SEBI Listing
	- Shareholding of the listed entity/ subsidiary (in case of transaction involving the subsidiary), whether direct or indirect, in the related party.	Nil
	- Where the related party is a partnership firm or a sole proprietorship concern or a body corporate without share capital, then capital contribution, if any, made by the listed entity/ subsidiary (in case of transaction involving the subsidiary).	NA
	- Shareholding of the related party, whether direct or indirect, in the listed entity/subsidiary (in case of transaction involving the subsidiary). Explanation: Indirect shareholding shall mean shareholding held through any person, over which the listed entity/Subsidiary/ related party has control (as defined under SEBI Listing Regulations). While calculating indirect shareholding, shareholding held by relatives shall also be considered.	NA
A(3)	**Details of previous transactions with the related party**	
1.	Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party during the last financial year. Explanation: Details need to be disclosed separately for listed entity and its subsidiary.	See tables below

SN	Category	Amount (₹ in Mn) FY2025-26
1)	Sale of Goods	2,641.17
2)	Receiving of Services	14.71
3)	Others	100.69
	Total	**2,756.58**

The details of transactions with Subsidiary (OneSource Specialty Pte Ltd) are as below:

SN	Category	Amount (₹ in Mn) FY2025-26
1)	Sale of Goods	102.19
2)	Others	0.12
	Total	**102.31**

<table>
<tr><th>SN</th><th>Particulars of the information</th><th>Information provided by the Management</th></tr>
<tr><td>2.</td><td>Total amount of all the transactions undertaken by the listed entity or subsidiary with the related party in the current financial year up to the quarter immediately preceding the quarter in which the approval is sought. (amount in crore including GST)</td><td>
<table>
<tr><th>SN</th><th>Category</th><th>Amount (₹ in Mn) Q1FY2026-27</th></tr>
<tr><td>1)</td><td>Sale of Goods</td><td>551.41</td></tr>
<tr><td>2)</td><td>Others</td><td>27.27</td></tr>
<tr><td></td><td>Total</td><td>578.68</td></tr>
</table>
The details of transactions with Subsidiary (OneSource Specialty Pte Ltd) are as below:
<table>
<tr><th>SN</th><th>Category</th><th>Amount (₹ in Mn) Q1FY2026-27</th></tr>
<tr><td>1)</td><td>Sale of Goods</td><td>13.37</td></tr>
<tr><td></td><td>Total</td><td>13.37</td></tr>
</table>
</td></tr>
<tr><td>3.</td><td>Any default, if any, made by a related party concerning any obligation undertaken by it under a transaction or arrangement entered into with the listed entity or its subsidiary during the last financial year.</td><td>No</td></tr>
<tr><td colspan="3">A(4) Amount of the proposed transaction(s)</td></tr>
<tr><td>1.</td><td>Amount of the proposed transactions being placed for approval in the meeting of the Audit Committee/ Members. (amount in crore including GST)</td><td>₹ 5,663.00 million (incl. transaction with Subsidiary ₹ 260.00 million)</td></tr>
<tr><td>2.</td><td>Whether the proposed transactions taken together with the transactions undertaken with the related party during the current financial year would render the proposed transaction a material RPT?</td><td>Yes</td></tr>
<tr><td>3.</td><td>Value of the proposed transactions as a percentage of the listed entity's annual consolidated turnover for the immediately preceding financial year.</td><td>39.84% (incl. transaction with Subsidiary)</td></tr>
<tr><td>4.</td><td>Value of the proposed transactions as a percentage of subsidiary's annual standalone turnover for the immediately preceding financial year (in case of a transaction involving the subsidiary, and where the listed entity is not a party to the transaction).</td><td>25.00%</td></tr>
<tr><td>5.</td><td>Value of the proposed transactions as a percentage of the related party's annual consolidated turnover (if consolidated turnover is not available, calculation to be made on standalone turnover of related party) for the immediately preceding financial year, if available.</td><td>26%</td></tr>
<tr><td>6.</td><td>Financial performance of the related party for the immediately preceding financial year:

Explanations: The above information is given on standalone basis.</td><td>
<table>
<tr><th>Particulars</th><th>Amount (₹ in Mn) for FY2025-26</th></tr>
<tr><td>Turnover</td><td>21,403.32</td></tr>
<tr><td>Profit After Tax</td><td>595.23</td></tr>
<tr><td>Net worth</td><td>24,385.79</td></tr>
</table>
</td></tr>
</table>

<table>
<tr><th>SN</th><th>Particulars of the information</th><th>Information provided by the Management</th></tr>
<tr><td colspan="3">A(5) Basic details of the proposed transaction</td></tr>
<tr><td>1.</td><td>Specific type of the proposed transaction (e.g. sale of goods/services, purchase of goods/services, giving loan, borrowing etc.)</td><td>Following the implementation of the Scheme pursuant to NCLT Order, OneSource has successfully acquired the soft gelatine business from Strides India. As a multimodal, pure-play specialty pharma CDMO, OneSource operates in the B2B segment, focusing on high-value contract development and manufacturing services. Strides USA in contrast, is a B2C-focused entity for over 13 years, supported by a robust workforce of more than 200 employees. With its deep-rooted presence and proven capabilities in the US market, it is strategically and operationally appropriate for OneSource to continue leveraging Strides USA for front-end operations in the region. All intercompany transactions between OneSource and Strides USA will be conducted at arm's length prices (ALP), in line with global transfer pricing standards. These transactions are independently assessed by a qualified third-party expert at the end of the financial year, ensuring transparency, regulatory compliance, and robust governance</td></tr>
<tr><td>2.</td><td>Details of each type of proposed transactions for FY2026-27</td><td>
<table>
<tr><th>SN</th><th>Category</th><th>Amount (₹ in Mn)</th></tr>
<tr><td>1)</td><td>Sale of Goods</td><td>5,000.00</td></tr>
<tr><td>2)</td><td>Receiving of Services</td><td>203.00</td></tr>
<tr><td>3)</td><td>Others</td><td>200.00</td></tr>
<tr><td></td><td>- Reimbursement of expenses</td><td>200.00</td></tr>
<tr><td></td><td>Total</td><td>5,403.00</td></tr>
</table>
The details of transactions with Subsidiary (OneSource Specialty Pte Ltd) are as below:
<table>
<tr><th>SN</th><th>Category</th><th>Amount (₹ in Mn) Q1FY2026-27</th></tr>
<tr><td>1)</td><td>Sale of Goods</td><td>100.00</td></tr>
<tr><td>2)</td><td>Receiving of Services</td><td>110.00</td></tr>
<tr><td>3)</td><td>Others</td><td>50.00</td></tr>
<tr><td></td><td>- Reimbursement of expenses</td><td>50.00</td></tr>
<tr><td></td><td>Total</td><td>260.00</td></tr>
</table>
</td></tr>
<tr><td>3.</td><td>Tenure of the proposed transaction (tenure in number of years or months to be specified)</td><td>April'26 to March'27</td></tr>
<tr><td>4.</td><td>Whether omnibus approval is being sought?</td><td>Yes</td></tr>
<tr><td>5.</td><td>Value of the proposed transaction during a financial year. If the proposed transaction will be executed over more than one financial year, provide estimated break-up financial year-wise.</td><td>₹ 5,663.00 million</td></tr>
<tr><td>6.</td><td>Justification as to why the RPTs proposed to be entered into are in the interest of the listed entity</td><td>As a multimodal, pure-play specialty pharma CDMO, OneSource operates in the B2B segment, focusing on high-value contract development and manufacturing services. Strides USA in contrast, is a B2C-focused, it is strategically appropriate for OneSource to continue leveraging Strides USA for front-end operations in the region.</td></tr>
<tr><td>7.</td><td>Details of the promoter(s)/ director(s) / key managerial personnel of the listed entity who have interest in the transaction, whether directly
or indirectly.
Explanation: Indirect interest shall mean interest held through any person over which an individual has control.</td><td>Arun Kumar is Non-Executive Director ('NED') and Chairman of OneSource.</td></tr>
<tr><td>8.</td><td>A copy of the valuation or other external party report, if any, shall be placed before the Audit Committee.</td><td>NA</td></tr>
<tr><td>9.</td><td>Other information relevant for decision making.</td><td>All important information forms part of the Statement setting out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice.</td></tr>
</table>

PART-B

Information to be provided only if a specific type of RPT as mentioned below is proposed to be undertaken and is in addition to Part A

B(1). Disclosure only in case of transactions relating to sale, purchase or supply of goods or services or any other similar business transaction and trade advances

1.	Bidding or other process, if any, applied for choosing a party for sale, purchase or supply of goods or services.	NA since this is specific in nature and not comparable
2.	Basis of determination of price.	The Pricing is determined basis the annual Transfer Pricing study by external third-party specialist, which is in accordance with applicable regulations
3.	In case of Trade advance (of upto 365 days or such period for which such advances are extended as per normal trade practice), if any, proposed to be extended to the related party in relation to the transaction, specify the following: a. Amount of Trade advance b. Tenure c. Whether same is self-liquidating?	NA

Annexure 4

GENERAL INFORMATION TO Members

1. Pursuant to the Scheme of Arrangement approved by Hon'ble National Company Law Tribunal ("NCLT") amongst OneSource and Strides Pharma Science Limited along with other group entities, shares were allotted to eligible Members. As part of the process, certain shares, particularly those where Member details were incomplete or unverified, were transferred to the Demat Suspense Account in accordance with regulatory requirements.

2. All shares of OneSource are in dematerialized form, including those held in the Unclaimed Suspense Account.

3. To claim these shares, eligible Members must submit demat account details and KYC documents to the Company's Registrar and Transfer Agent (RTA).

4. Upon verification, the shares will be transferred to the Member's demat account.

5. Documents required by Members to claim shares from the Demat Suspense Account:

   a) Request letter signed by the Member(s)

   b) Client Master List (CML) attested by the DP/ Member(s)

   c) Self-attested PAN card (with date)

   d) Self-attested address proof (with date)

   e) Copy of Allotment/Transaction statement, if available

   Note: Please submit the required documents to the RTA at the earliest to complete the transfer process.

6. **Withdrawal of the requirement of Freezing of Folios**

   SEBI vide its Circular SEBI/ HO/ MIRSD/ POD-1/ P/ CIR/2023/181 dated November 17, 2023 has done away with the requirement of freezing of folios and referring frozen folios to the administering authority under the Benami Transactions (Prohibitions) Act, 1988 and/ or Prevention of Money Laundering Act, 2002.

7. **Inspection of Documents**

   All documents referred in this AGM Notice shall be available for inspection electronically. In addition, following documents shall also be available for inspection electronically:

   - Certificate from the Secretarial Auditor relating to the Company's Stock Options under SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

   - Register of Directors and Key Managerial Personnel and their shareholding, and the Register of Contracts or Arrangements in which the Directors are interested, maintained under the Companies Act, 2013.

   Members seeking to inspect the above documents can also send an email to investor-relations@onesourcecdmo.com

8. **Scrutinizer for the AGM**

   Pradeep Bheemsen Kulkarni and/ or Partners of V Sreedharan and Associates, Practicing Company Secretary (ICSI Membership No. F7260 and CP:7835) of M/s. V Sreedharan & Associates, Company Secretaries, Bengaluru, has been appointed as the Scrutinizer to scrutinize the remote e-voting process and e-voting at the AGM in a fair and transparent manner.

   Scrutinizer shall submit his Report on the resolutions proposed to be passed at the AGM to the Chairperson or Company Secretary of the Company after completion of the scrutiny.

   Results of the meeting along with Scrutinizer Report shall be declared by the Chairperson or the Company Secretary of the Company on or before Friday, September 25, 2026 and shall be communicated to BSE Limited and The National Stock Exchange of India Limited ("Stock Exchanges") where the equity shares of the Company are listed. Results of the meeting shall also be displayed on the notice board at the Registered Office of the Company for a period of 3 (Three) days, on the Company's website at www.onesourcecdmo.com and on the website of RTA at www.integratedregistry.in

Instructions for attending AGM through Video Conference/ Other Audio-Visual Means (VC/OAVM) Facility

1. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) the Secretarial Standards on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs from time to time the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as e-voting on the date of the AGM will be provided by NSDL.

Members are advised to update their mobile number and email Id in their Demat accounts to access e-Voting facility.

2. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.onesourcecdmo.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www. nseindia.com respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. www.evoting.nsdl.com.

3. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular issued from time to time

4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Members (Members holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

5. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.

The instructions for members for remote e-voting and joining general meeting are as follows:-

The remote e-voting period begins on Friday, September 18, 2026 at 09:00 Hours (IST) and ends on Tuesday, September 22, 2026 at 17:00 Hours (IST). The remote e-voting will not be allowed beyond the aforesaid date and the remote e-voting module shall be forthwith disabled by NSDL upon expiry of the aforesaid period.

The Members whose names appear in the Register of Members / Beneficial Owners as on the record date **(cut-off date) i.e. Wednesday, September 16, 2026**, may cast their vote electronically. The voting right of Members shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date.

A person who is not a Member as at the Cut-off date should treat this Notice for information purposes only. Once the vote on a Resolution is cast by the Member, the Member shall not be allowed to change it subsequently.

In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

Members are requested to apply for consolidation of folios, in case their holdings are maintained in multiple folios.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meeting for Individual Members holding securities in demat mode

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Members holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Members are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.Login method for Individual Members holding securities in demat mode is given below:

Type of Members	Login Method
Individual Members holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to **e-Voting website of NSDL** for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner"** icon under "**Login**" which is available under '**IDeAS**' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on "**Access to e-Voting**" under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "**Register Online for IDeAS Portal**" or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Members/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience. **NSDL Mobile App is available on** App Store Google Play

Type of Members	Login Method
Individual Members holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
Individual Members (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Members holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Members holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Members holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meeting for Members other than Individual Members holding securities in demat mode and Members holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/ Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for Members other than Individual Members are given below:

   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?

      (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.

      (ii) If your email ID is not registered, please follow steps mentioned below **in process for those Members whose email ids are not registered.**

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:

   a) Click on "**Forgot User Details/Password?**"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.

   b) **Physical User Reset Password?"** (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.

   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.

   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.

8. Now, you will have to click on "Login" button.

9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for Members

1. Institutional Members (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to compliance@sreedharancs.com with a copy marked to evoting@nsdl.com. Institutional Members (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Members and e-voting user manual for Members available at the download section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 or send a request to evoting@nsdl.com.

Process for those Members whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of Member, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to CS@onesourcecdmo.com.

2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to CS@onesourcecdmo.comIf you are an Individual Members holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A) i.e. Login method for e-Voting and joining virtual meeting for Individual Members holding securities in demat mode.**

3. Alternatively, Shareholder/Members may send a request to evoting@nsdl.com for procuring user id and password for e-voting by providing above mentioned documents.

4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual Members holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Members are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.

2. Only those Members/ Members, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.

3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system.** After successful login, you can see link of "VC/ OAVM" placed under "**Join meeting**" menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Members who would like to express their views/ask questions during the meeting may register themselves as a speaker and send their request mentioning their

name, demat account number/folio number, email id, mobile number at cs@onesourcecdmo.com from 18th September 2026 (9:00 Hours (IST)) to 21st September 2026 (17:00 Hours (IST)).

6. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

7. Members who would like to express their views/ have questions may send their questions in advance mentioning their name demat account number/ folio number, email id, mobile number at cs@ onesourcecdmo.com. The same will be replied by the company suitably.

   When a pre-registered speaker is invited to speak at the meeting but he/ she does not respond, the next speaker will be invited to speak.

   Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM. Only questions of the Members holding shares as on the cut-off date will be considered.